Martin Shkreli, We Hardly Knew Ye
Actually, we know Martin Shkreli, CEO of KaloBios Pharmaceuticals (NASDAQ: KBIO), all too well. The brash young man was arrested by the Federal Bureau of Investigations yesterday in Manhattan, on charges of fraud relating to his days at a hedge. Just weeks before, as then-CEO of privately held Turing Pharmaceuticals, he became the poster child of drug price gougers, having boosted the price of a long-marketed generic drug by 5000%, from $13.50 per pill to $750. The revelations in a New York Times story brought swift recriminations from all sides, including presidential candidates. The most striking note for us, as health care database wonks, is that Shkreli launched his first biotech... Read More »Pfizer’s Acquisition Trail
Pfizer Inc. (NYSE: PFE) is a well-oiled acquisition machine, with at least 107 announced acquisitions since 1998. Including yesterday’s announcement of its $160 billion deal for Irish drug maker Allergan plc (NYSE: AGN), the largest-ever health care transaction, Pfizer has spent more than $461 billion on those 107 deals. Thirteen of those disclosed prices of $1 billion or more. Here are the five biggest deals announced. Company AcquiredDatePrice Allergan plcNovember 23, 2014$160 billion Warner-Lambert CompanyNovember 4, 1999$114 billion Wyeth, Inc. January 26, 2009$68 billion Pharmacia CorporationJuly 15, 2002$56 billion Hospira, Inc. February 5, 2015$17... Read More »Health Care M&A Passes Half-a-Trillion $ Mark
Thanks to today’s announcement that Pfizer Inc. (NYSE: PFE) and Allergan plc (NYSE: AGN) agreed to a $160 billion merger, 2015’s total for health care mergers and acquisitions now stands at $549.4 billion. That’s 42% higher than last year’s full total of $387 billion, an amount we thought would stand for at least a few years. Deal volume for the year is now about 1,285, just 2% below last year’s record of 1,312 transactions. And there’s still a month left to go in 2015. Stay tuned. Read More »Hanmi Pharmaceutical Deals with Sanofi, Janssen
Korean pharmaceutical company Hanmi Pharmaceutical Co., Ltd. popped up on the healthcare M&A radar last week with two collaboration announcements. First was an agreement with French drug maker Sanofi (NYSE: SNY) to grant the worldwide license to a yet-to-be developed portfolio of experimental, long-acting diabetes treatments. Sanofi paid an upfront fee of €400 million ($434,820,000) and is eligible for up to €3.5 billion in development, registration and sales milestone, as well as double digit royalties on net sales. The second deal, with Janssen Pharmacticals, Inc. (NYSE: JNJ), was for the rights to oxyntomodulin-based therapies, including Hanmi’s NM12525A. Janssen paid $105... Read More »Allergan Licenses Dry Eye Treatment
Allergan plc (NYSE: AGN) is making inroads in the dry eye disease treatment area, paying $50 million upfront to license Mimetogen Pharmaceuticals’ tavilermide (MIM-D3), a topical formulation of a novel small molecule TrkA agonist. Allergan will also fund Phase 3 development of the drug, which has shown the ability to improve patient-reported blurriness and poor vision. The deal bolsters Allergan’s mid- to late-stage pipeline in eye care products. Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
